Research and development intensity and the Inflation Reduction Act's prescription drug provisions | Brookings

Last wee Ben Graham and I released a paper examining R&D spending by large pharmaceutical manufacturers. We show that the evidence does not support the idea that R&D effort has declined as a result of the Inflation Reduction Act. In fact the evidence suggests that if anything, it has increased.

International reference pricing for prescription drugs | Brookings Christen Linke Young, Richard Frank, and Rachel Sachs explore the potential role of international prices in the U.S. drug policy today.

Christen Linke Young, Rachel Sachs and I just put out a paper reviewing issues related to adopting International Reference Prices for prescription drugs. The link is: www.brookings.edu/articles/int...

The Trump administration's NIH and FDA cuts will negatively impact patients Additional cuts in funding and staffing at the NIH and FDA could portend serious risks to the American public.

Sherry Glied and I posted a blog noting that cuts to NIH and FDA are grounded in misunderstanding of the basis for grant programs and a failure to consider the health impacts of staff reductions at FDA. See www.brookings.edu/articles/the...

Cumulative net earnings of drugs selected or likely to be selected for negotiation Richard Frank and Yihan Shi investigate the net sales of drugs selected for the second round of negotiation and future drug selections.

My colleague Yihan Shi and I posted the linked paper showing that all prescription drugs slated for Medicare negotiation and likely to soon be negotiated are making healthy returns on R&D investments. www.brookings.edu/articles/cum...

Today Sherry Glied and I posted a commentary on Health Affairs Forefront outlining how the HHS reorganization runs counter to RFK's stated goals for the department and any notion of improved efficiency. See the post at www.healthaffairs.org/content/fore...

Medicaid Cuts Kick Down on People Caught in the Opioid Epidemic Proposed cuts to Medicaid could undo advances in treatment for opioid use disorders, risking more overdoses, deaths and stress on the U.S. health system

Today scientific American published my op ed on Medicaid cuts and the opioid epidemic. It can be found at www.scientificamerican.com/article/medi...

Thanks Ezra its a small effort on a huge problem

The role of Medicaid in addressing the opioid epidemic Richard G. Frank reviews the role of Medicaid in treating opioid use disorders and the impacts of policies intended to cut funding.

I posted a paper today with so e facts to highlight
Possible consequences of Medicaid cuts www.brookings.edu/articles/the...

Assessing the Effect of the Medicare Part D Redesign This Viewpoint focuses on the Manufacturer Discount Program, identifying 4 key themes of interest to policymakers that may be affected by its Part D redesign.

The following paper may be of interest to folks following the IRA nam10.safelinks.protection.outlook.com?url=https%3A...

Workplace injuries in a changing labor market Richard G. Frank and Julia Paris present research on the projected changes in the U.S workforce and its impacts on occupational injury risks.

www.brookings.edu/articles/wor...

Richard Frank's response to commentary on government support of innovation Richard G. Frank responds in an op-ed to claims regarding investments in drug research and development and drug pricing negotiations.

www.brookings.edu/articles/ric...